Follistatin, Gene Therapy, Muscle Mass, and Longevity
<p>Frailty and Metabolic Syndrome cast gaunt (and flabby) shadows over our aging world; the need for new therapeutics has never been so urgent.</p>
<p>Follistatin gene therapy addresses two pressing epidemics: frailty from sarcopenia (age-related muscle loss) and Metabolic Syndrome — a constellation of issues including insulin insensitivity, hypertension, high cholesterol, and excess body fat (Cornier, 2008).</p>
<p>Heart disease is the leading cause of death in the developed world; aging and Metabolic Syndrome are its primary contributors.</p>
<p>Follistatin gene therapy has been successfully used in patients with muscular dystrophy (Mendel, 2012; Mendel, 2015).</p>
<p><a href="https://bioviva-science.medium.com/follistatin-gene-therapy-muscle-mass-and-longevity-fb77bce1cbac"><strong>Website</strong></a></p>